The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
Clinical trial NCT04933526 · UNKNOWN
Trial details
- NCT number
- NCT04933526
- Sponsor
- Shenzhen Second People's Hospital
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-01
- Primary completion
- 2023-04-30
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.